New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before...
PolyCrystalLine SpA has been inspected by FDA and received the GMP certification from AIFA for the physico-chemical analyses. For any request please contact us soon....
We invite you to join us at our stand #3C62 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact marco.glucini@polycrystalline.it...
Polycrystalline can be entrusted with your most sensitive projects for method development and validation of API’s intermediates, raw materials and finished products.
New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intell...
Registration Now Open CF@Bo n.10 is dedicated to Professor Joel Bernstein (12/9/1941 - 2/1/2019) ABOUT THE CONVENTION The investigation and optimization of crystal forms are at the forefront of industrial as well as fundamental research. The event will bring together acad...
PolyCrystalLine received the authorization N°101/2017 from the Italian Ministry of Healthfor the study and chemical/physical analysis of controlled substances. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for client...
We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it....
We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it....
From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project&rdquo...
Polycrystalline is expanding its HPAPI offerings, up to OEB 5 level of containment for the synthesis, study and development of anti-cancer and cytotoxic APIs. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients wit...
PolyCrystalLine s.r.l. received the approval from French Health Ministry as a CRO for R&D activities, the French companies who use our services can benefit of a tax credit in compliance with the article 244 quater B of the French general code of taxes. (see the PDF attached) ...
PolyCrystalLine received the audit from the Health Agency for the cGMP certification.
PolyCrystalLine discovered a novel crystalline form of Minodronic Acid and filed a patent application. For additional information contact info@polycrystalline.it...
ABSTRACT: The structure−property relationships of new polymorphs of the chiral herbicide imazamox were investigated by X-ray diffraction, hot stage microscopy (HSM), and differential scanning calorimetry (DSC). Four different polymorphs of imazamox(R) were found. The relationship betwe...
Polycrystalline, CSV Life Science e Pharma-Hub organizzano la Giornata di Studio sul tema "SOSTANZE ALTAMENTE ATTIVE: RISCHI E CONTENIMENTO" che si terrà a Formia il giorno 05 Aprile 2018. Sedi delle giornate di studio Formia 1ª edizione 05 Aprile 2018 - Kora Park Hotel, Via ...
